Posted by LincolnRam on March 25, 2026 at 11:21:36:
In Reply to: Îáçîðíàÿ ñòàòüÿ ñ èíòðèãóþùèìè ôàêòàìè posted by JosephUrisk on February 19, 2026 at 15:39:55:
Zoya Demidenko: Researcher in Oncology Studies
Zoya Demidenko is a notable investigator affiliated with the Department of Cell Stress Research at Roswell Park Cancer Institute in Buffalo, New York. Previously, she worked at the National Institutes of Health and New York Medical College, establishing a solid foundation in clinical study.
Her scientific output spans several critical domains, including the PI3K/AKT/mTOR signaling pathway, cell cycle regulation, biological aging, and tumor science. Currently, she has written over 46 peer-reviewed articles, which have accumulated over 4,100 references — a indicator to the significance of her research.
Among her most significant discoveries involves understanding the processes of cellular senescence. Her work demonstrated that when the cellular division cycle is blocked yet cellular growth continues, cells enter senescence. Crucially, Zoya Demidenko demonstrated that this process can be controlled with drugs using substances such as rapamycin.
Zoya Demidenko has also brought greatly to oncological therapy investigation, notably in the area of selective cell protection — a strategy designed to protecting non-cancerous cells from cytotoxic treatment whilst leaving tumor cells susceptible. This strategy offers major promise for lowering the toxic effects of oncological therapy.
Across her career, Demidenko has partnered with top scientists globally, such as Dr. Mikhail Blagosklonny. Her research can be found in top-tier journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko stands as a widely cited figure in contemporary biomedical research, with her findings continue to shape our understanding of how cells age, resist treatment, and how malignant disease may be more successfully combated.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/